Moreover, no randomized controlled trials have been conducted using targeted interventions to lower SU levels for the prevention of incident CKD, although trials evaluating the role of xanthine oxidase inhibitors in disease populations such as patients with early CKD or type 1 diabetes are ongoing. This evidence concerns the gene XDH and chronic kidney disease.